NEWS AND MEDIA
Recent News
Second Circuit Court Upholds Purdue Pharma’s Plan of Reorganization on Appeal
Stamford, Conn. – Today, the U.S. Court of Appeals for the Second Circuit ruled in favor of Purdue Pharma’s chapter 11 Plan of Reorganization (the “Plan”), affirming the bankruptcy court’s September 2021 confirmation order. “The Second Circuit’s ruling is a victory…
Purdue Pharma L.P. to Provide Funding Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection
Purdue Pharma L.P. to Provide Funding Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection Stamford, Conn., March 28, 2023 – Purdue Pharma L.P. is accepting proposals for investigator-initiated research…
Harm Reduction Therapeutics to Receive Additional Funding for its Low-Cost Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma
Harm Reduction Therapeutics to Receive Additional Funding for its Low-Cost Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma $9 million in funding for commercial readiness approved by the Bankruptcy Court Harm Reduction Therapeutics’ RiVive™…
FDA Grants Priority Review for Nalmefene Prefilled Syringe for the Treatment of Known or Suspected Opioid Overdose
Stamford, Conn., Jan, 18, 2023 – Purdue Pharma L.P. (“Purdue”) announced that FDA has accepted and granted priority review to the company’s Abbreviated New Drug Application (ANDA) for Nalmefene Hydrochloride (HCl) injection, 2 mg/2 mL (1mg/1mL) Prefilled Syringe.*…
Prescription Drug Safety Network Reached More Than 22,000 Students with Prescription Drug Safety Digital Education During 2021-22 School Year
STAMFORD, Conn. – Nov. 2, 2022 – Purdue Pharma L.P. lauds the Prescription Drug Safety Network (“the Network”) for educating thousands of students about prescription drug safety during the 2021-2022 school year. The Network, of which Purdue Pharma L.P. is a founding…
Purdue Pharma Introduces Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) in the U.S. for the Treatment of Known or Suspected Overdose with Natural or Synthetic Opioids
Company will distribute injectable nalmefene for no profit as part of its commitment to help abate the opioid crisis STAMFORD, Conn. – June 21, 2022 – Purdue Pharma L.P. announced today that Nalmefene Hydrochloride injection, 2mg/2mL (1mg/1mL) is now available in the…
Harm Reduction Therapeutics to Receive Additional Funding for the Development of its Over-the-Counter Opioid Overdose Reversal Medication from Purdue Pharma after Bankruptcy Court Approval
Stamford, Conn., March 23, 2022 – Harm Reduction Therapeutics (HRT) will receive up to $11 million of additional financial support from Purdue Pharma L.P. to advance its development of a low-cost, over-the-counter (OTC) naloxone nasal spray in the United States.…
Purdue Pharma L.P. to Provide Opportunities for Investigator-Initiated Research to Examine Opioid Overdose Reversal in Emergency Medicine Settings
Stamford, Conn., March 17, 2022 – Purdue Pharma L.P. is accepting proposals for investigator-initiated research (IIR) to assess opioid overdose reversal in Emergency Department (ED) and Emergency Medical Service (EMS) settings. Because we recognize there is value in…
FDA Approves Nalmefene HCl Injection, 2mg/2mL (1mg/1mL) for the Treatment of Known or Suspected Opioid Overdose with Natural or Synthetic Opioids
STAMFORD, Conn. – Feb. 23, 2022 – Purdue Pharma L.P. announced today that FDA has approved its abbreviated new drug application for Nalmefene hydrochloride injection, 2mg/2mL (1mg/1mL).1 Nalmefene is an opioid antagonist indicated for the complete or partial reversal…
Purdue Pharma Statement with Respect to District Court Decision Vacating Bankruptcy Court’s Confirmation of the Plan of Reorganization
STAMFORD, Conn. – Purdue Pharma L.P. today announced its intent to appeal today’s ruling by the United States District Court for the Southern District of New York, which vacated the Bankruptcy Court’s September 2021 order confirming its chapter 11 plan of…